Can a multiple sclerosis drug help preserve insulin production in type 1 diabetes?

NCT ID NCT07258394

Recruiting now Disease control Sponsor: Nanjing Medical University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether dimethyl fumarate, a drug already used for multiple sclerosis, can protect the pancreas's insulin-producing cells in adults recently diagnosed with type 1 diabetes. Ninety participants will take either the drug or a placebo twice daily for 24 weeks, alongside their usual insulin. The main goal is to see if the drug helps maintain natural insulin production, measured by a C-peptide test after a mixed meal.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dimethyl fumarate
What this could lead to: If it works, this could help preserve the body's ability to produce some insulin, potentially reducing the amount of insulin injections needed.
What could go wrong: This is an early Phase 3 trial with only 90 participants. The drug may not protect beta cells better than placebo, and side effects like flushing or stomach issues are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TYPE 1 DIABETES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

type 1 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TYPE 1 DIABETES

Contacts and locations

Locations

Deparement of Endocrinology and Metabolism, The First Affiliated Hospital with Nanjing Medical University
RECRUITING

Nanjing, Jiangsu, 210029, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.